Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Cambridge: AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase ...

Subcutaneous emphysema is the medical term for air becoming trapped in tissues beneath the skin. It is rare, but may occur as a result of trauma, injury, infection, or certain medical procedures.

AstraZeneca inks license pact with Alteogen for subcutaneous formulations of multiple oncology assets: Cambridge, UK Tuesday, March 18, 2025, 12:00 Hrs [IST] AstraZeneca, a global ...

Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ...

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of ...

A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.